• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Verona Pharma plc (Amendment)

    2/6/23 2:36:14 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRNA alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

                

    Verona Pharma PLC


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    925050106


    (CUSIP Number)

    December 30, 2022


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 925050106

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 24,909,288
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 26,770,960
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    26,770,960
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.43%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 925050106

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 24,909,288
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 26,770,960
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    26,770,960
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.43%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 925050106

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 24,909,288
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 26,770,960
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    26,770,960
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.43%
    12. TYPE OF REPORTING PERSON

    HC

    Item 1.
    (a) Name of Issuer
    Verona Pharma PLC
    (b) Address of Issuer's Principal Executive Offices
    3 More London Riverside
    London SE1 2RE
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    925050106
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Exhibit A directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    See attached Exhibit A.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2023

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2023

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2023


    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.


    EXHIBIT B

    JOINT FILING AGREEMENT

    The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Verona Pharma PLC is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.


    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2023

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2023

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2023

    Get the next $VRNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRNA

    DatePrice TargetRatingAnalyst
    7/14/2025Buy → Neutral
    H.C. Wainwright
    7/1/2025$170.00Outperform
    Wolfe Research
    4/28/2025$100.00Buy
    TD Cowen
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    1/10/2025$68.00Buy
    ROTH MKM
    10/3/2024$50.00Overweight
    Wells Fargo
    5/22/2023$35.00 → $38.00Buy
    Jefferies
    9/19/2022$27.00Outperform
    Wedbush
    More analyst ratings

    $VRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Verona Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Verona Pharma from Buy to Neutral

    7/14/25 8:43:04 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Verona Pharma with a new price target

    Wolfe Research initiated coverage of Verona Pharma with a rating of Outperform and set a new price target of $170.00

    7/1/25 8:22:56 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Verona Pharma with a new price target

    TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

    4/28/25 8:38:21 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck Completes Acquisition of Verona Pharma

    Acquisition strengthens Merck's cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma") acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market. "The Verona Pharma acquisition strengthens and complements our portfolio of treatments for patients with cardio-pulmonary diseases to include Ohtuvayr

    10/7/25 6:45:00 AM ET
    $MRK
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

    LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the proposal for MSD to acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $1

    10/6/25 4:05:00 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

    LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE:MRK) ("Merck") through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for Merck to acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion (the "Transaction"). The Transaction is being implemented by way

    9/24/25 4:05:00 PM ET
    $MRK
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Fisher Andrew returned 1,349,887 units of Ordinary Shares to the company and converted options into 931,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    10/8/25 4:45:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Zaccardelli David returned 15,461,424 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    10/8/25 4:44:12 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rickard Kathleen A. returned 3,564,852 units of Ordinary Shares to the company and converted options into 1,131,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    10/8/25 4:43:18 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    SEC Filings

    View All

    SEC Form EFFECT filed by Verona Pharma plc

    EFFECT - Verona Pharma plc (0001657312) (Filer)

    11/17/25 12:15:05 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Verona Pharma plc

    SCHEDULE 13G - Verona Pharma plc (0001657312) (Subject)

    11/14/25 4:27:13 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc

    SCHEDULE 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/25 4:00:03 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/18/24 4:20:05 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/7/24 6:57:21 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/7/24 6:56:12 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Financials

    Live finance-specific insights

    View All

    Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

    4/29/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

    LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

    4/15/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

    2/27/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 5:46:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 4:50:28 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verona Pharma plc

    SC 13G - Verona Pharma plc (0001657312) (Subject)

    11/14/24 4:31:56 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

    ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E

    4/29/21 2:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care